藥明康德、藥明合聯、聯邦及榮昌升逾4%-8% 惟聖諾瀉20%尋底
醫藥股今天個別發展。藥明系止跌回升,藍籌藥明康德(02359.HK)及藥明生物(02269.HK)扭三連跌,股價由今早低位39.7元及14.04元,掉頭回升,午後高見43.2元及14.94元,現報42.75元及14.68元,回升4.3%及1.7%。藥明合聯(02268.HK)扭四連跌,高低見17.12元/15.06元,現報16.6元,反覆回升6.3%。
榮昌生物(09995.HK)反覆續升8.3%報29.9元。騰盛博藥-B(02137.HK)重越10天線,最高見1.07元,現報1.03元,回升6.2%。維亞生物(01873.HK)回升5.9%報0.54元。
上週五發盈喜的聯邦製藥(03933.HK)承上週五探頂強勢,今天進一步突破2018年5月所創高位9.535元,最高見9.88元,創逾12年高,現報9.7元,續升4.5%。
國藥(01099.HK)、宜明昂科-B(01541.HK)及康希諾生物(06185.HK)升逾1%-2%。
然而,聖諾醫藥-B(02257.HK)執董戴曉暢所持9.95萬股遭強制出售,股價再創上市新低,最低見7.96元,現報8.044元,急挫20%。
百心安-B(02185.HK)反覆跌9.2%報2.56元。半新股君聖泰醫藥-B(02511.HK)續跌4.6%報7.64元。綠葉製藥(02186.HK)回吐3.6%報2.95元。
翰森製藥(03692.HK)、金斯瑞(01548.HK)、石藥(01093.HK)、康諾亞-B(02162.HK)及開拓藥業-B(9939.HK)跌近1%-3%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.